Literature DB >> 31623855

Current status and limitations of immunotherapy for breast cancer.

Yoshihisa Tokumaru1, Daniel Joyce1, Kazuaki Takabe2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31623855      PMCID： PMC7028447          DOI： 10.1016/j.surg.2019.09.018

Source DB:  PubMed          Journal:  Surgery        ISSN： 0039-6060            Impact factor:   3.982


× No keyword cloud information.
  5 in total

1.  Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

Authors:  Sherene Loi; Anita Giobbie-Hurder; Andrea Gombos; Thomas Bachelot; Rina Hui; Giuseppe Curigliano; Mario Campone; Laura Biganzoli; Hervé Bonnefoi; Guy Jerusalem; Rupert Bartsch; Manuela Rabaglio-Poretti; Roswitha Kammler; Rudolf Maibach; Mark J Smyth; Angelo Di Leo; Marco Colleoni; Giuseppe Viale; Meredith M Regan; Fabrice André
Journal:  Lancet Oncol       Date:  2019-02-11       Impact factor: 41.316

2.  Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.

Authors:  S Adams; S Loi; D Toppmeyer; D W Cescon; M De Laurentiis; R Nanda; E P Winer; H Mukai; K Tamura; A Armstrong; M C Liu; H Iwata; L Ryvo; P Wimberger; H S Rugo; A R Tan; L Jia; Y Ding; V Karantza; P Schmid
Journal:  Ann Oncol       Date:  2019-03-01       Impact factor: 32.976

3.  Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer.

Authors:  Sumana Narayanan; Tsutomu Kawaguchi; Li Yan; Xuan Peng; Qianya Qi; Kazuaki Takabe
Journal:  Ann Surg Oncol       Date:  2018-05-16       Impact factor: 5.344

4.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

5.  CDK4/6 inhibition triggers anti-tumour immunity.

Authors:  Shom Goel; Molly J DeCristo; April C Watt; Haley BrinJones; Jaclyn Sceneay; Ben B Li; Naveed Khan; Jessalyn M Ubellacker; Shaozhen Xie; Otto Metzger-Filho; Jeremy Hoog; Matthew J Ellis; Cynthia X Ma; Susanne Ramm; Ian E Krop; Eric P Winer; Thomas M Roberts; Hye-Jung Kim; Sandra S McAllister; Jean J Zhao
Journal:  Nature       Date:  2017-08-16       Impact factor: 49.962
  5 in total
  20 in total

1.  Exploitation of Sulfated Glycosaminoglycan Status for Precision Medicine of Triplatin in Triple-Negative Breast Cancer.

Authors:  James D Hampton; Erica J Peterson; Nicholas P Farrell; Jennifer E Koblinski; Samantha J Katner; Tia H Turner; Mohammad A Alzubi; J Chuck Harrell; Mikhail G Dozmorov; Joseph B McGee Turner; Pam J Gigliotti; Vita Kraskauskiene; Mayuri Shende; Michael O Idowu; Madhavi Puchalapalli; Bin Hu; Larisa Litovchick; Eriko Katsuta; Kazuaki Takabe
Journal:  Mol Cancer Ther       Date:  2021-11-23       Impact factor: 6.009

2.  High Expression of miR-34a Associated with Less Aggressive Cancer Biology but Not with Survival in Breast Cancer.

Authors:  Yoshihisa Tokumaru; Eriko Katsuta; Masanori Oshi; Judith C Sporn; Li Yan; Lan Le; Nobuhisa Matsuhashi; Manabu Futamura; Yukihiro Akao; Kazuhiro Yoshida; Kazuaki Takabe
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

Review 3.  Chimeric antigen receptor T-cell immunotherapy in breast cancer: development and challenges.

Authors:  Sara Toulouie; Gary Johanning; Yihui Shi
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

4.  Gas plasma irradiation of breast cancers promotes immunogenicity, tumor reduction, and an abscopal effect in vivo.

Authors:  Hamed Mahdikia; Fariba Saadati; Eric Freund; Udo S Gaipl; Keivan Majidzadeh-A; Babak Shokri; Sander Bekeschus
Journal:  Oncoimmunology       Date:  2020-12-29       Impact factor: 8.110

5.  Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival.

Authors:  Masanori Oshi; Yoshihisa Tokumaru; Fernando A Angarita; Lan Lee; Li Yan; Ryusei Matsuyama; Itaru Endo; Kazuaki Takabe
Journal:  Sci Rep       Date:  2021-06-15       Impact factor: 4.379

6.  High Expression of microRNA-143 is Associated with Favorable Tumor Immune Microenvironment and Better Survival in Estrogen Receptor Positive Breast Cancer.

Authors:  Yoshihisa Tokumaru; Mariko Asaoka; Masanori Oshi; Eriko Katsuta; Li Yan; Sumana Narayanan; Nobuhiko Sugito; Nobuhisa Matsuhashi; Manabu Futamura; Yukihiro Akao; Kazuhiro Yoshida; Kazuaki Takabe
Journal:  Int J Mol Sci       Date:  2020-05-01       Impact factor: 5.923

7.  The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2- Breast Cancer.

Authors:  Masanori Oshi; Hideo Takahashi; Yoshihisa Tokumaru; Li Yan; Omar M Rashid; Masayuki Nagahashi; Ryusei Matsuyama; Itaru Endo; Kazuaki Takabe
Journal:  Cells       Date:  2020-07-08       Impact factor: 6.600

8.  M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer.

Authors:  Masanori Oshi; Yoshihisa Tokumaru; Mariko Asaoka; Li Yan; Vikas Satyananda; Ryusei Matsuyama; Nobuhisa Matsuhashi; Manabu Futamura; Takashi Ishikawa; Kazuhiro Yoshida; Itaru Endo; Kazuaki Takabe
Journal:  Sci Rep       Date:  2020-10-06       Impact factor: 4.379

9.  Integrated Analysis of the Transcriptome Profile Reveals the Potential Roles Played by Long Noncoding RNAs in Immunotherapy for Sarcoma.

Authors:  Boran Pang; Yongqiang Hao
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

10.  Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer.

Authors:  Masanori Oshi; Tsutomu Kawaguchi; Li Yan; Xuan Peng; Qianya Qi; Wanqing Tian; Amy Schulze; Kerry-Ann McDonald; Sumana Narayanan; Jessica Young; Song Liu; Luc Gt Morris; Timothy A Chan; Pawel Kalinski; Ryusei Matsuyama; Eigo Otsuji; Itaru Endo; Kazuaki Takabe
Journal:  Am J Cancer Res       Date:  2021-07-15       Impact factor: 5.942
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.